OTC BOIL TFM MOVES SIX INGREDIENTS TO CATEGORY III (MORE STUDY) FROM CATEGORY II
Executive Summary
The tentative final monograph (TFM) for OTC boil remedies reclassifies magnesium sulfate, benzocaine, camphor, ichthammol, juniper tar and phenol to Category III. Published in the Jan. 26 Federal Register, the TFM also places sulfur, which was not included in the original panel report, as a Category III ingredient for boils. The panel report, published in 1982, classified 24 ingredients as Category II based on the OTC review panel's recommendations. The TFM explains that the panel did not review specific ingredients but placed all of the ingredients in Category II "because of its belief that the self-treatment of boils is not desirable because improper treatment or a delay in receiving proper professional treatment may cause the infection to spread." Commerce Drug was the only drug company to submit comments on the panel report. The company markets an OTC boil product, Boil-Ease, that contains several of the reclassified ingredients. FDA explained that it is reclassifying the six ingredients based on data in Commerce's submission and data that had been submitted to the OTC review panel for boil products. Studies cited by Commerce Drug, "show that human skin is remarkably resistant to staphylococcal and streptococcal infection," the TFM states. Therefore, "the agency believes that a safety concern that infection may spread may not be a major problem." However, the TFM adds, "the agency concludes that additional information is needed before the agency can fully address the panel's concerns that improper treatment or a delay in receiving professional treatment for boils may cause the infection to spread."
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth